FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development ; volume:15 ; number:1 ; day:3 ; month:9 ; year:2020 ; pages:1-8 ; date:12.2020
Orphanet journal of rare diseases ; 15, Heft 1 (3.9.2020), 1-8, 12.2020
- Creator
-
Miller, Kathleen L.
Mueller, Christine
Liu, Gumei
Miller Needleman, Katherine I.
Maynard, Janet
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-020-01514-5
- URN
-
urn:nbn:de:101:1-2020102420120745024831
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miller, Kathleen L.
- Mueller, Christine
- Liu, Gumei
- Miller Needleman, Katherine I.
- Maynard, Janet
- SpringerLink (Online service)
Other Objects (12)
Hostels, ORPHAN GRANTS
Do investors value the FDA orphan drug designation?
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Additively manufactured medical products – the FDA perspective
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Investigating the landscape of US orphan product approvals
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
FDA
FDA
FDA
FDA
Hostels, ORPHAN GRANTS
Do investors value the FDA orphan drug designation?
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Additively manufactured medical products – the FDA perspective
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Investigating the landscape of US orphan product approvals
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
FDA
FDA
FDA
FDA
Hostels, ORPHAN GRANTS
Do investors value the FDA orphan drug designation?
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Additively manufactured medical products – the FDA perspective
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
Investigating the landscape of US orphan product approvals
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
FDA
FDA
FDA